1. Home
  2. LFVN vs KPTI Comparison

LFVN vs KPTI Comparison

Compare LFVN & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lifevantage Corporation (Delaware)

LFVN

Lifevantage Corporation (Delaware)

HOLD

Current Price

$6.26

Market Cap

145.2M

Sector

Health Care

ML Signal

HOLD

Logo Karyopharm Therapeutics Inc.

KPTI

Karyopharm Therapeutics Inc.

HOLD

Current Price

$7.78

Market Cap

94.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LFVN
KPTI
Founded
N/A
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
145.2M
94.6M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
LFVN
KPTI
Price
$6.26
$7.78
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$35.00
$22.17
AVG Volume (30 Days)
192.9K
282.6K
Earning Date
02-04-2026
02-18-2026
Dividend Yield
2.90%
N/A
EPS Growth
143.91
N/A
EPS
0.78
N/A
Revenue
$228,877,000.00
$142,530,000.00
Revenue This Year
$1.54
$3.82
Revenue Next Year
$7.00
N/A
P/E Ratio
$7.97
N/A
Revenue Growth
16.77
N/A
52 Week Low
$5.69
$3.51
52 Week High
$27.38
$12.45

Technical Indicators

Market Signals
Indicator
LFVN
KPTI
Relative Strength Index (RSI) 44.95 68.33
Support Level $5.80 $7.01
Resistance Level $6.33 $7.44
Average True Range (ATR) 0.33 0.46
MACD 0.04 0.03
Stochastic Oscillator 68.75 84.49

Price Performance

Historical Comparison
LFVN
KPTI

About LFVN Lifevantage Corporation (Delaware)

Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.

About KPTI Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

Share on Social Networks: